The high health authority also specifies, in accordance with its previous opinions, that the use of mRNA vaccines should be given to the first administration.
Le Monde With Reuters
The High health authority (HAS) recommended, Monday, February 21, to reserve vaccination With the Janssen vaccine in some cases at risk of severe forms of CVIV-19 pending the conclusions of the European Medicines Agency (AEM).
According to the HAS, the preliminary results of a study suggest a slight increased risk of myocardial infarction within two weeks of injection of Janssen vaccine in adults under 75 years.
The independent public authority recalls, however, that it is preliminary data and that they must be confirmed by other studies at the international level, including a review of the EMA.
Reporting expected injections with Janssen Vaccine
The HAS thus recommends, waiting for the conclusions of the EMA, to postpone the injections planned with the Janssen vaccine, except in persons at risk of severe form of the disease which present a contraindication to vaccines. RNA messenger (mRNA).
The has precise has, in accordance with the opinions it has already made, that the use of mRNA vaccines should be given to the first dose as well as for the recall dose when possible, including for People who have already received a dose of the Janssen vaccine in first injection, because of their best efficiency.